• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

症状和胸部 X 线筛查在 HIV 阴性的成年人和 HIV 状态未知的成年人中的活动性肺结核。

Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status.

机构信息

Anja van't Hoog, Health Research & Training Consultancy, Utrecht, Netherlands.

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

出版信息

Cochrane Database Syst Rev. 2022 Mar 23;3(3):CD010890. doi: 10.1002/14651858.CD010890.pub2.

DOI:10.1002/14651858.CD010890.pub2
PMID:35320584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9109771/
Abstract

BACKGROUND

Systematic screening in high-burden settings is recommended as a strategy for early detection of pulmonary tuberculosis disease, reducing mortality, morbidity and transmission, and improving equity in access to care. Questioning for symptoms and chest radiography (CXR) have historically been the most widely available tools to screen for tuberculosis disease. Their accuracy is important for the design of tuberculosis screening programmes and determines, in combination with the accuracy of confirmatory diagnostic tests, the yield of a screening programme and the burden on individuals and the health service.

OBJECTIVES

To assess the sensitivity and specificity of questioning for the presence of one or more tuberculosis symptoms or symptom combinations, CXR, and combinations of these as screening tools for detecting bacteriologically confirmed pulmonary tuberculosis disease in HIV-negative adults and adults with unknown HIV status who are considered eligible for systematic screening for tuberculosis disease. Second, to investigate sources of heterogeneity, especially in relation to regional, epidemiological, and demographic characteristics of the study populations.

SEARCH METHODS

We searched the MEDLINE, Embase, LILACS, and HTA (Health Technology Assessment) databases using pre-specified search terms and consulted experts for unpublished reports, for the period 1992 to 2018. The search date was 10 December 2018. This search was repeated on 2 July 2021.

SELECTION CRITERIA

Studies were eligible if participants were screened for tuberculosis disease using symptom questions, or abnormalities on CXR, or both, and were offered confirmatory testing with a reference standard. We included studies if diagnostic two-by-two tables could be generated for one or more index tests, even if not all participants were subjected to a microbacteriological reference standard. We excluded studies evaluating self-reporting of symptoms.

DATA COLLECTION AND ANALYSIS

We categorized symptom and CXR index tests according to commonly used definitions. We assessed the methodological quality of included studies using the QUADAS-2 instrument. We examined the forest plots and receiver operating characteristic plots visually for heterogeneity. We estimated summary sensitivities and specificities (and 95% confidence intervals (CI)) for each index test using bivariate random-effects methods. We analyzed potential sources of heterogeneity in a hierarchical mixed-model.

MAIN RESULTS

The electronic database search identified 9473 titles and abstracts. Through expert consultation, we identified 31 reports on national tuberculosis prevalence surveys as eligible (of which eight were already captured in the search of the electronic databases), and we identified 957 potentially relevant articles through reference checking. After removal of duplicates, we assessed 10,415 titles and abstracts, of which we identified 430 (4%) for full text review, whereafter we excluded 364 articles. In total, 66 articles provided data on 59 studies. We assessed the 2 July 2021 search results; seven studies were potentially eligible but would make no material difference to the review findings or grading of the evidence, and were not added in this edition of the review. We judged most studies at high risk of bias in one or more domains, most commonly because of incorporation bias and verification bias. We judged applicability concerns low in more than 80% of studies in all three domains. The three most common symptom index tests, cough for two or more weeks (41 studies), any cough (21 studies), and any tuberculosis symptom (29 studies), showed a summary sensitivity of 42.1% (95% CI 36.6% to 47.7%), 51.3% (95% CI 42.8% to 59.7%), and 70.6% (95% CI 61.7% to 78.2%, all very low-certainty evidence), and a specificity of 94.4% (95% CI 92.6% to 95.8%, high-certainty evidence), 87.6% (95% CI 81.6% to 91.8%, low-certainty evidence), and 65.1% (95% CI 53.3% to 75.4%, low-certainty evidence), respectively. The data on symptom index tests were more heterogenous than those for CXR. The studies on any tuberculosis symptom were the most heterogeneous, but had the lowest number of variables explaining this variation. Symptom index tests also showed regional variation. The summary sensitivity of any CXR abnormality (23 studies) was 94.7% (95% CI 92.2% to 96.4%, very low-certainty evidence) and 84.8% (95% CI 76.7% to 90.4%, low-certainty evidence) for CXR abnormalities suggestive of tuberculosis (19 studies), and specificity was 89.1% (95% CI 85.6% to 91.8%, low-certainty evidence) and 95.6% (95% CI 92.6% to 97.4%, high-certainty evidence), respectively. Sensitivity was more heterogenous than specificity, and could be explained by regional variation. The addition of cough for two or more weeks, whether to any (pulmonary) CXR abnormality or to CXR abnormalities suggestive of tuberculosis, resulted in a summary sensitivity and specificity of 99.2% (95% CI 96.8% to 99.8%) and 84.9% (95% CI 81.2% to 88.1%) (15 studies; certainty of evidence not assessed).

AUTHORS' CONCLUSIONS: The summary estimates of the symptom and CXR index tests may inform the choice of screening and diagnostic algorithms in any given setting or country where screening for tuberculosis is being implemented. The high sensitivity of CXR index tests, with or without symptom questions in parallel, suggests a high yield of persons with tuberculosis disease. However, additional considerations will determine the design of screening and diagnostic algorithms, such as the availability and accessibility of CXR facilities or the resources to fund them, and the need for more or fewer diagnostic tests to confirm the diagnosis (depending on screening test specificity), which also has resource implications. These review findings should be interpreted with caution due to methodological limitations in the included studies and regional variation in sensitivity and specificity. The sensitivity and specificity of an index test in a specific setting cannot be predicted with great precision due to heterogeneity. This should be borne in mind when planning for and implementing tuberculosis screening programmes.

摘要

背景

系统筛查在高负担环境中被推荐作为早期发现肺结核病的一种策略,可以降低死亡率、发病率和传播率,并改善获得医疗服务的公平性。询问症状和胸部 X 线摄影(CXR)一直是最广泛可用的工具,用于筛查结核病。它们的准确性对于结核病筛查计划的设计很重要,并结合确认诊断测试的准确性,确定了筛查计划的产量以及对个人和卫生服务的负担。

目的

评估询问一种或多种肺结核症状或症状组合、CXR 以及这些组合作为工具在 HIV 阴性成年人和 HIV 状况未知的成年人中检测细菌学确诊的肺结核病的敏感性和特异性,这些人被认为有资格接受系统的结核病筛查。其次,调查异质性的来源,特别是与研究人群的区域、流行病学和人口统计学特征有关。

检索方法

我们使用预定义的搜索词在 MEDLINE、Embase、LILACS 和 HTA(卫生技术评估)数据库中进行了检索,并咨询了专家以获取未发表的报告,检索时间为 1992 年至 2018 年。2021 年 7 月 2 日再次进行了检索。

选择标准

如果参与者使用症状问题、CXR 异常或两者都进行结核病筛查,并提供参考标准的确认性检测,则研究符合入选标准。如果可以生成一个或多个指标测试的诊断性四格表,即使并非所有参与者都接受了微观细菌学参考标准,我们也将包括这些研究。我们排除了评估自我报告症状的研究。

数据收集和分析

我们根据常用定义对症状和 CXR 指标测试进行了分类。我们使用 QUADAS-2 工具评估了纳入研究的方法学质量。我们通过观察森林图和受试者工作特征图来检查异质性。我们使用双变量随机效应方法估计了每个指标测试的汇总敏感性和特异性(和 95%置信区间(CI))。我们在分层混合模型中分析了异质性的潜在来源。

主要结果

电子数据库搜索确定了 9473 个标题和摘要。通过专家咨询,我们确定了 31 份全国结核病患病率调查的报告为合格(其中 8 份已经包含在电子数据库搜索中),我们通过参考文献检查确定了 957 篇潜在相关文章。在去除重复项后,我们评估了 10415 个标题和摘要,其中 430 个(4%)进行了全文审查,此后我们排除了 364 篇文章。共有 66 篇文章提供了 59 项研究的数据。我们评估了 2021 年 7 月 2 日的搜索结果;有 7 项研究可能符合条件,但不会对审查结果或证据的分级产生实质性影响,因此未在此版本的审查中添加。我们认为大多数研究在一个或多个领域存在高偏倚风险,最常见的原因是合并偏倚和验证偏倚。在所有三个领域中,我们都认为超过 80%的研究存在低应用问题。三个最常见的症状指标测试,咳嗽持续两周或以上(41 项研究)、任何咳嗽(21 项研究)和任何结核病症状(29 项研究),其汇总敏感性为 42.1%(95%CI 36.6%至 47.7%)、51.3%(95%CI 42.8%至 59.7%)和 70.6%(95%CI 61.7%至 78.2%),特异性为 94.4%(95%CI 92.6%至 95.8%)、87.6%(95%CI 81.6%至 91.8%)和 65.1%(95%CI 53.3%至 75.4%),均为低确定性证据)。症状指标测试的数据比 CXR 的数据更具异质性。任何结核病症状的研究最具异质性,但导致这种变异的变量数量最少。症状指标测试也显示出区域差异。任何 CXR 异常(23 项研究)的汇总敏感性为 94.7%(95%CI 92.2%至 96.4%,非常低确定性证据)和 CXR 异常提示结核病(19 项研究)的 84.8%(95%CI 76.7%至 90.4%,低确定性证据),特异性为 89.1%(95%CI 85.6%至 91.8%,低确定性证据)和 95.6%(95%CI 92.6%至 97.4%,高确定性证据)。敏感性比特异性更具异质性,并且可以通过区域差异来解释。添加持续咳嗽两周或以上,无论是对任何(肺部)CXR 异常还是对提示结核病的 CXR 异常,都将产生 99.2%(95%CI 96.8%至 99.8%)和 84.9%(95%CI 81.2%至 88.1%)的汇总敏感性和特异性(15 项研究;证据确定性未评估)。

作者结论

症状和 CXR 指标测试的汇总估计可能为正在实施结核病筛查的任何特定环境或国家提供筛查和诊断算法的选择依据。CXR 指标测试的高敏感性,无论是否并行出现症状问题,都表明结核病患者的检出率很高。然而,其他考虑因素将决定筛查和诊断算法的设计,例如 CXR 设施的可用性和可及性或为其提供资金的资源,以及为了确认诊断(取决于筛查测试的特异性)而需要进行更多或更少的诊断测试的需求,这也会带来资源方面的影响。由于纳入研究中的方法学局限性和敏感性和特异性的区域差异,应该谨慎解释这些审查结果。由于存在异质性,特定环境中指标测试的敏感性和特异性不能非常精确地预测。在规划和实施结核病筛查计划时应牢记这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/9835fc72bc96/nCD010890-TST-009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/bf523119a115/nCD010890-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d26033671dfa/nCD010890-FIG-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/c9f090480979/nCD010890-FIG-03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/f704719aa361/nCD010890-FIG-04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ecd111c77b23/nCD010890-FIG-05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/4fe84858fbd1/nCD010890-FIG-06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/1d9ea13c17eb/nCD010890-FIG-07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/2dda182a53c5/nCD010890-FIG-08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/48d62b299a56/nCD010890-FIG-09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ae434f12e62b/nCD010890-FIG-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/b8b4fc0c7759/nCD010890-FIG-11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/035a4f074704/nCD010890-FIG-12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/43884a0fcac8/nCD010890-FIG-13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/48460a04562c/nCD010890-FIG-14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/7a4124cd8226/nCD010890-FIG-15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/83da54e31c5e/nCD010890-FIG-16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/0b6acbd8749c/nCD010890-FIG-17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d6d4e47526f2/nCD010890-FIG-18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/1034105ef895/nCD010890-FIG-19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/bd15176aac11/nCD010890-FIG-20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/2736c91d834a/nCD010890-TST-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ae4c9506ebb3/nCD010890-TST-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/31342e611e32/nCD010890-TST-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d0a8c54b8773/nCD010890-TST-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/8249ab8c5e20/nCD010890-TST-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/672eb87b5163/nCD010890-TST-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/8c54bb476015/nCD010890-TST-007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/35205486d812/nCD010890-TST-008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/9835fc72bc96/nCD010890-TST-009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/bf523119a115/nCD010890-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d26033671dfa/nCD010890-FIG-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/c9f090480979/nCD010890-FIG-03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/f704719aa361/nCD010890-FIG-04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ecd111c77b23/nCD010890-FIG-05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/4fe84858fbd1/nCD010890-FIG-06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/1d9ea13c17eb/nCD010890-FIG-07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/2dda182a53c5/nCD010890-FIG-08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/48d62b299a56/nCD010890-FIG-09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ae434f12e62b/nCD010890-FIG-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/b8b4fc0c7759/nCD010890-FIG-11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/035a4f074704/nCD010890-FIG-12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/43884a0fcac8/nCD010890-FIG-13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/48460a04562c/nCD010890-FIG-14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/7a4124cd8226/nCD010890-FIG-15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/83da54e31c5e/nCD010890-FIG-16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/0b6acbd8749c/nCD010890-FIG-17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d6d4e47526f2/nCD010890-FIG-18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/1034105ef895/nCD010890-FIG-19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/bd15176aac11/nCD010890-FIG-20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/2736c91d834a/nCD010890-TST-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/ae4c9506ebb3/nCD010890-TST-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/31342e611e32/nCD010890-TST-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/d0a8c54b8773/nCD010890-TST-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/8249ab8c5e20/nCD010890-TST-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/672eb87b5163/nCD010890-TST-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/8c54bb476015/nCD010890-TST-007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/35205486d812/nCD010890-TST-008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fc/9109771/9835fc72bc96/nCD010890-TST-009.jpg

相似文献

1
Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status.症状和胸部 X 线筛查在 HIV 阴性的成年人和 HIV 状态未知的成年人中的活动性肺结核。
Cochrane Database Syst Rev. 2022 Mar 23;3(3):CD010890. doi: 10.1002/14651858.CD010890.pub2.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.Xpert MTB/RIF Ultra assay 用于儿童结核病和利福平耐药检测。
Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD013359. doi: 10.1002/14651858.CD013359.pub3.
4
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
5
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
6
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
7
Airway physical examination tests for detection of difficult airway management in apparently normal adult patients.气道体格检查用于检测表面上正常的成年患者的困难气道管理情况。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD008874. doi: 10.1002/14651858.CD008874.pub2.
8
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
9
Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.经胸多普勒超声心动图用于检测成人肺动脉高压。
Cochrane Database Syst Rev. 2022 May 9;5(5):CD012809. doi: 10.1002/14651858.CD012809.pub2.
10
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.首次就诊时磁共振灌注成像用于鉴别低级别与高级别胶质瘤
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.

引用本文的文献

1
Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.在赞比亚和南非,对胸部X光异常但无结核病证据的结核病患病率调查参与者进行了为期9个月的中位随访后的临床结果。
PLOS Glob Public Health. 2025 Jun 20;5(6):e0003787. doi: 10.1371/journal.pgph.0003787. eCollection 2025.
2
What Is the Optimal Community-Based Tuberculosis Screening Algorithm for People Who Inject Drugs in a High-Burden Setting?在高负担环境下,针对注射吸毒者的最佳社区结核病筛查算法是什么?
Open Forum Infect Dis. 2025 Mar 26;12(4):ofaf191. doi: 10.1093/ofid/ofaf191. eCollection 2025 Apr.
3

本文引用的文献

1
Screening tests for active pulmonary tuberculosis in children.儿童活动性肺结核筛查试验。
Cochrane Database Syst Rev. 2021 Jun 28;6(6):CD013693. doi: 10.1002/14651858.CD013693.pub2.
2
High TB burden and low notification rates in the Philippines: The 2016 national TB prevalence survey.菲律宾的高结核负担和低通报率:2016 年全国结核患病率调查。
PLoS One. 2021 Jun 4;16(6):e0252240. doi: 10.1371/journal.pone.0252240. eCollection 2021.
3
Accuracy and Incremental Yield of the Chest X-Ray in Screening for Tuberculosis in Uganda: A Cross-Sectional Study.
How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined tuberculosis screening tests.
如何诊断移民中的结核病?对综述的系统评价及决策树分析建模,以评估单一和联合结核病筛查试验的特性。
Eur Respir J. 2025 Jul 24;66(1). doi: 10.1183/13993003.02000-2024. Print 2025 Jul.
4
The performance of computer-aided detection for chest radiography in tuberculosis screening: a population-based retrospective cohort study.计算机辅助检测在肺结核筛查胸部X线摄影中的性能:一项基于人群的回顾性队列研究。
Emerg Microbes Infect. 2025 Dec;14(1):2470998. doi: 10.1080/22221751.2025.2470998. Epub 2025 Apr 28.
5
Unrecognized Tuberculosis: Risk Factors for Smear-Positive/Cavitary Asymptomatic Cases.未被识别的结核病:涂片阳性/有空洞的无症状病例的危险因素。
Open Forum Infect Dis. 2025 Mar 22;12(4):ofaf176. doi: 10.1093/ofid/ofaf176. eCollection 2025 Apr.
6
Continuous digital cough monitoring during 6-month pulmonary tuberculosis treatment.6个月肺结核治疗期间的持续数字咳嗽监测
ERJ Open Res. 2025 Mar 24;11(2). doi: 10.1183/23120541.00655-2024. eCollection 2025 Mar.
7
Diagnostic accuracy of screening and diagnostic tests used in a state-wide tuberculosis prevalence survey in India.印度一项全州结核病患病率调查中使用的筛查和诊断测试的诊断准确性。
Sci Rep. 2025 Mar 18;15(1):9305. doi: 10.1038/s41598-025-94346-x.
8
Persistently high TB prevalence in Nairobi County neighbourhoods, 2015-2022.2015 - 2022年内罗毕县各社区结核病患病率持续居高不下。
PLOS Glob Public Health. 2025 Feb 18;5(2):e0003849. doi: 10.1371/journal.pgph.0003849. eCollection 2025.
9
The yield of tuberculosis contact investigation in São Paulo, Brazil: a community-based cross-sectional study.巴西圣保罗结核病接触者调查的产出:一项基于社区的横断面研究。
Epidemiol Infect. 2025 Jan 30;153:e20. doi: 10.1017/S0950268824001675.
10
Community-based active-case finding for tuberculosis: navigating a complex minefield.基于社区的结核病主动病例发现:穿越复杂雷区
BMC Glob Public Health. 2024 Feb 8;2(1):9. doi: 10.1186/s44263-024-00042-9.
乌干达胸部X光筛查结核病的准确性和增量收益:一项横断面研究
Tuberc Res Treat. 2021 Mar 19;2021:6622809. doi: 10.1155/2021/6622809. eCollection 2021.
4
Community-based active case-finding interventions for tuberculosis: a systematic review.基于社区的主动病例发现干预措施在结核病中的应用:系统评价。
Lancet Public Health. 2021 May;6(5):e283-e299. doi: 10.1016/S2468-2667(21)00033-5. Epub 2021 Mar 22.
5
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.Xpert MTB/RIF 和 Xpert Ultra 检测用于筛查成人肺结核和利福平耐药,无论有无症状。
Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013694. doi: 10.1002/14651858.CD013694.pub2.
6
A comparison of digital chest radiography and Xpert MTB/RIF in active case finding for tuberculosis.数字胸部 X 光摄影与 Xpert MTB/RIF 在结核病活动性筛查中的比较。
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):934-940. doi: 10.5588/ijtld.19.0764.
7
National tuberculosis prevalence surveys in Africa, 2008-2016: an overview of results and lessons learned.非洲国家结核病患病率调查,2008-2016 年:结果概述及经验教训。
Trop Med Int Health. 2020 Nov;25(11):1308-1327. doi: 10.1111/tmi.13485. Epub 2020 Oct 12.
8
Detecting tuberculosis in pregnant and postpartum women in Eswatini.在斯威士兰检测孕妇和产后妇女的结核病。
Afr J Lab Med. 2020 Jul 30;9(1):837. doi: 10.4102/ajlm.v9i1.837. eCollection 2020.
9
Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada.在美国和加拿大,新近接触者中 TNF-α、IFN-γ 和 IL-10 对结核病的预测价值。
BMC Infect Dis. 2020 Jul 31;20(1):553. doi: 10.1186/s12879-020-05185-2.
10
Contribution of Xpert MTB/RIF to tuberculosis case finding among pregnant women in Botswana.Xpert MTB/RIF 在博茨瓦纳孕妇结核病病例发现中的作用。
Public Health Action. 2020 Jun 21;10(2):76-81. doi: 10.5588/pha.19.0077.